Abstract:

Objective To investigate the effects of intracoronary and intravenous application of tirofiban on platelet aggregation rate (PAR) in patients with acute coronary syndrome (ACS). Methods Eighteen patients with ACS undergoing percutaneous coronary intervention(PCI) were randomized into intracoronary tirofiban bolus group (group IC, n=9) and intravenous tirofiban bolus group (group IV, n=9). The changes of PAR at different time points after tirofiban application in two groups and the differences in the degree of PAR decrease between two groups were analysed, and the prevalences of bleeding and thrombocytopenia were also recorded. Results PAR decreased after treatment with tirofiban in both groups, and there were significant differences between PAR after treatment and that before treatment (P＜0.05). In coronary artery, the trend of PAR decrease in group IC was more significant than that in group IV (P=0.062). In peripheral vessel, there was no significant difference in the degree of PAR decrease between two groups (P＞0.05). There was no significant difference in the prevalences of bleeding and thrombocytopenia between two groups (P＞0.05). Conclusion Both intracoronary and intravenous application of tirofiban can effectively decrease PAR in coronary artery and peripheral vessel, and may not increase the risk of bleeding.

Key words: acute coronary syndrome, percutaneous coronary intervention, tirofiban, platelet aggregation, intracoronary, intravenous